Stocktoria
4D Molecular Therapeutics, Inc. FDMT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-12-11
4D Molecular Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -187.2% | -507678.4% | -544.6% | -3516.5% | -395.5% |
| Net margin | -164.4% | -434778.4% | -486.6% | -3435.4% | -395.4% |
| FCF margin | -128.6% | -373975.7% | -379.1% | -3139.1% | -433.8% |
| Return on assets | -24.7% | -28.7% | -29.7% | -41.1% | -20.2% |
| Return on equity | -27.7% | -31.5% | -32.8% | -46.5% | -22.3% |
| Current ratio | 9.39 | 14.92 | 15.65 | 14.02 | 15.69 |
| Revenue growth | 230194.6% | -99.8% | 562.3% | -82.7% | 32.5% |
Source: SEC EDGAR filings · CIK 0001650648 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.